hydroxychloroquine has been researched along with Recrudescence in 69 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies have shown the effect of hydroxychloroquine in the treatment and prevention of recurrence of brucellosis." | 9.51 | Combination of doxycycline, streptomycin and hydroxychloroquine for short-course treatment of brucellosis: a single-blind randomized clinical trial. ( Emami, K; Hashmi, SH; Majzoobi, MM; Soltanian, AR, 2022) |
| "Glucocorticoid (GC)-dependent, colchicine-resistant idiopathic recurrent pericarditis (IRP) remains a clinical challenge." | 7.96 | Hydroxychloroquine for colchicine-resistant glucocorticoid-dependent idiopathic recurrent pericarditis: A pilot observational prospective study. ( Antonatou, K; Antonopoulos, AS; Hadziyannis, E; Lazaros, G; Lazarou, E; Leontsinis, I; Ritis, K; Simantiris, S; Skendros, P; Tousoulis, D; Vassilopoulos, D; Vlachopoulos, C, 2020) |
| " A case of psoriatic onychoperiostitis precipitated by hydroxychloroquine therapy is reported." | 7.69 | Recurrent psoriatic onychoperiostitis induced by hydroxychloroquine. ( Cribier, B; Javier, RM; Kuntz, JL; Pflumio, F; Sibilia, J, 1995) |
| "High-dose hydroxychloroquine is rarely used in the treatment of porphyria cutanea tarda (PCT)." | 7.68 | High-dose hydroxychloroquine treatment of porphyria cutanea tarda. ( Petersen, CS; Thomsen, K, 1992) |
| "Hydroxychloroquine (HCQ) is an anti-rheumatic drug commonly used in the treatment of rheumatoid arthritis and systemic lupus erythematosus." | 6.84 | Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. ( Eklund, KK; Hartman, O; Kovanen, PT; Lehtonen, J; Sinisalo, J, 2017) |
| " Studies included were trials in which: (1) the participants were classified as having GCA by the 1990 ACR criteria or biopsy proven disease; (2) parallel-group randomised control of at least 16 weeks duration had been conducted with at least 20 participants; (3) the design included either alternative adjunct immunosuppressant regimens, alternative GCs dosing or routes of administration; and (4) outcome data was included on either relapse rates or rates of infection." | 6.50 | Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. ( Loke, YK; MacGregor, AJ; Watts, RA; Yates, M, 2014) |
| "Previous studies have shown the effect of hydroxychloroquine in the treatment and prevention of recurrence of brucellosis." | 5.51 | Combination of doxycycline, streptomycin and hydroxychloroquine for short-course treatment of brucellosis: a single-blind randomized clinical trial. ( Emami, K; Hashmi, SH; Majzoobi, MM; Soltanian, AR, 2022) |
| "Though autoimmune disorders and prolactinoma were reported in GM, a coexisting condition of SLE, prolactinoma, and granulomatous mastitis has rarely been observed in one patient." | 5.40 | An SLE patient with prolactinoma and recurrent granulomatous mastitis successfully treated with hydroxychloroquine and bromocriptine. ( Shi, TY; Yang, YJ; Zhang, FC; Zhang, LN, 2014) |
| "In 1990 the Utrecht rheumatoid arthritis cohort study group started a clinical trial in which patients with recent onset of rheumatoid arthritis (<1 year) were randomised into four treatment groups: hydroxychloroquine (n = 169); intramuscular gold (n = 163); methotrexate (n = 166); and pyramid (n = 64)." | 5.11 | A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. ( Bijlsma, JW; Blaauw, AA; Haanen, HC; Jacobs, JW; Schenk, Y; van Albada-Kuipers, GA; Verstappen, SM, 2005) |
| "Recurrences of COVID-19 were observed in a patient with long-term usage of hydroxychloroquine, leflunomide, and glucocorticoids due to her 30-year history of rheumatoid arthritis (RA)." | 5.05 | A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab. ( Cai, S; Dong, L; Li, M; Sun, W, 2020) |
| " Hydroxychloroquine and other ordinary antirheumatic drugs slow down or may even prevent the progression of palindromic rheumatism into chronic rheumatoid arthritis." | 4.90 | [Palindromic rheumatism or incipient rheumatoid arthritis--chances of drug therapy]. ( Julkunen, H, 2014) |
| "A morning standard dose of 250 mcg tetracosactide (Synacthen test) was given in 25 consecutive patients (13 rheumatoid arthritis, 2 psoriatic arthritis, 5 systemic lupus erythematosus, 2 dermatomyositis, 1 systemic sclerosis, 2 temporal arteritis) at the time of relapse upon small reductions (1-2 mg daily) of low prednisolone dose (<7." | 4.12 | Impaired adrenal cortex reserve in patients with rheumatic and musculoskeletal diseases who relapse upon tapering of low glucocorticoid dose. ( Filippa, MG; Panopoulos, S; Sfikakis, PP; Spanos, E; Spanos, G; Tektonidou, MG; Yavropoulou, MP, 2022) |
| "Glucocorticoid (GC)-dependent, colchicine-resistant idiopathic recurrent pericarditis (IRP) remains a clinical challenge." | 3.96 | Hydroxychloroquine for colchicine-resistant glucocorticoid-dependent idiopathic recurrent pericarditis: A pilot observational prospective study. ( Antonatou, K; Antonopoulos, AS; Hadziyannis, E; Lazaros, G; Lazarou, E; Leontsinis, I; Ritis, K; Simantiris, S; Skendros, P; Tousoulis, D; Vassilopoulos, D; Vlachopoulos, C, 2020) |
| " Renewed remission was obtained with additional infliximab, and was maintained with azathioprine for 12 months before the patient again presented with symmetrical polyarthritis." | 3.73 | [Symmetric polyarthritis in a patient with Churg-Strauss syndrome]. ( Aries, PM; Reinhold-Keller, E, 2005) |
| " It was diagnosed to be a case of palindromic rheumatism clinically and treated with hydroxychloroquine." | 3.71 | Palindromic rheumatism. ( Singhal, S; Zahid, M, 2002) |
| " A case of psoriatic onychoperiostitis precipitated by hydroxychloroquine therapy is reported." | 3.69 | Recurrent psoriatic onychoperiostitis induced by hydroxychloroquine. ( Cribier, B; Javier, RM; Kuntz, JL; Pflumio, F; Sibilia, J, 1995) |
| "High-dose hydroxychloroquine is rarely used in the treatment of porphyria cutanea tarda (PCT)." | 3.68 | High-dose hydroxychloroquine treatment of porphyria cutanea tarda. ( Petersen, CS; Thomsen, K, 1992) |
| "Hydroxychloroquine (HCQ) is an anti-rheumatic drug commonly used in the treatment of rheumatoid arthritis and systemic lupus erythematosus." | 2.84 | Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. ( Eklund, KK; Hartman, O; Kovanen, PT; Lehtonen, J; Sinisalo, J, 2017) |
| "Oral prednisone alone was used in 50 of the 59 patients (mean initial dose 1 mg/kg body weight/day)." | 2.70 | Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. ( Arnal, C; Bierling, P; Godeau, B; Hachulla, E; Léone, J; Papo, T; Piette, JC; Roudot-Thoraval, F; Schaeffer, A; Taillan, B, 2002) |
| "After the first discharge, she got a recurrence of COVID-19 during her home isolation, and then returned to hospital and continued the previous therapy." | 2.66 | Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review. ( Cao, J; Fan, L; He, F; Hu, K; Lei, M; Luo, Q; Qin, S; Shao, X; Yang, L; Yu, N, 2020) |
| " Studies included were trials in which: (1) the participants were classified as having GCA by the 1990 ACR criteria or biopsy proven disease; (2) parallel-group randomised control of at least 16 weeks duration had been conducted with at least 20 participants; (3) the design included either alternative adjunct immunosuppressant regimens, alternative GCs dosing or routes of administration; and (4) outcome data was included on either relapse rates or rates of infection." | 2.50 | Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. ( Loke, YK; MacGregor, AJ; Watts, RA; Yates, M, 2014) |
| "A minority of patients who acquire acute Q fever will subsequently develop chronic Q fever endocarditis, which often manifests in valvular insufficiency." | 2.49 | Cardiac manifestations of Q fever infection: case series and a review of the literature. ( Farivar, RS; Gunn, TM; Raz, GM; Turek, JW, 2013) |
| "Linear lupus panniculitis of the scalp presenting as alopecia along Blaschko's lines had so far been reported exclusively in five East Asians." | 2.48 | Linear lupus panniculitis of the scalp presenting as alopecia along Blaschko's lines: a distinct variant of lupus panniculitis in East Asians? ( Chen, YA; Hsu, CK; Lee, JY; Yang, CC, 2012) |
| "Six cases of cheilitis granulomatosa, a rare inflammatory disorder of unknown origin, are reported." | 2.38 | Cheilitis granulomatosa: report of six cases and review of the literature. ( Allen, CM; Camisa, C; Hamzeh, S; Stephens, L, 1990) |
| "There were neither recurrences nor relevant major adverse effects in all the five KFD cases treated with hydroxychloroquine." | 1.51 | Pediatric Kikuchi-Fujimoto disease: A clinicopathologic study and the therapeutic effects of hydroxychloroquine. ( Chen, YY; Chiou, YH; Huang, HH; Huang, YF; Lee, HS; Lin, YC; Liu, PY; Nong, BR, 2019) |
| "SDC measurement decreases the risk for disease-related events, potentially through more optimal dosing or improved compliance." | 1.48 | The effect of measuring serum doxycycline concentrations on clinical outcomes during treatment of chronic Q fever. ( Bleeker-Rovers, CP; de Regt, MJA; Hoepelman, AIM; Kampschreur, LM; Oosterheert, JJ; van Roeden, SE; Vermeulen Windsant, A; Wever, PC, 2018) |
| "Cancer recurrence after initial diagnosis and treatment is a major cause of breast cancer (BC) mortality, which results from the metastatic outbreak of dormant tumour cells." | 1.48 | Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. ( Green, JE; Hunter, KW; Nini, R; Vera-Ramirez, L; Vodnala, SK, 2018) |
| "Hydroxychloroquine treatment significantly decreased (p < 0." | 1.48 | Immunomodulatory effects of hydroxychloroquine on Th1/Th2 balance in women with repeated implantation failure. ( Ghaffari Novin, M; Ghasemnejad, T; Ghasemnejad-Berenji, H; Ghasemnejad-Berenji, M; Hajshafiha, M; Hashemi, SM; Ilkhanizadeh, B; Nazarian, H; Sadeghpour, S, 2018) |
| "malariae infection with clinical recrudescence after directly observed administration of artemether/lumefantrine." | 1.46 | Genomic Characterization of Recrudescent Plasmodium malariae after Treatment with Artemether/Lumefantrine. ( Anstey, NM; Auburn, S; Berriman, M; Huang, GKL; Marfurt, J; Marr, I; Newbold, CI; Otto, TD; Price, RN; Rutledge, GG; Sanders, M; White, NJ, 2017) |
| "Last, we show that the recurrence rate of an adverse pregnancy outcome persisted at 30% despite treatment intervention." | 1.42 | Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study. ( Botta, A; Bucourt, M; Carbillon, L; Chollet-Martin, S; Chudzinski, A; Cornelis, F; Costedoat-Chalumeau, N; De Carolis, S; Emmanuelli, V; Fain, O; Hachulla, E; Masseau, A; Mekinian, A; Montestruc, F; Nicaise, P; Revaux, A; Subtil, D; Theulin, A, 2015) |
| "Juvenile systemic lupus erythematosus (JSLE) is a rare multisystem autoimmune disease with broad heterogeneity of clinical manifestations." | 1.42 | [Juvenile systemic lupus erythematosus with unusual manifestation of lupus-associated panniculitis]. ( Hashemie, H; Hoff, NP; Homey, B; Klossowski, N; Meller, S; Neubert, J; Oommen, PT; Reifenberger, J, 2015) |
| "Though autoimmune disorders and prolactinoma were reported in GM, a coexisting condition of SLE, prolactinoma, and granulomatous mastitis has rarely been observed in one patient." | 1.40 | An SLE patient with prolactinoma and recurrent granulomatous mastitis successfully treated with hydroxychloroquine and bromocriptine. ( Shi, TY; Yang, YJ; Zhang, FC; Zhang, LN, 2014) |
| "Most patients had at least one recurrence (18/23, 78%)." | 1.39 | Long-term outcome in idiopathic granulomatous mastitis: a western multicentre study. ( Cabane, J; Chiche, L; Costedoat-Chalumeau, N; Cottereau, A; De Faucal, P; Graveleau, J; Hachulla, E; Hamidou, M; Hello, M; Lavigne, C; Néel, A; Rondeau-Lutz, M; Seiberras, S; Tournemaine, N, 2013) |
| "Six years later, she developed right flank pain." | 1.39 | Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy. ( Baek, YH; Cho, DS; Chung, WT; Han, SY; Kang, SH; Lee, SW; Park, IC, 2013) |
| "The onset of facial palsy has been linked with Gougerot-Sjögren's syndrome." | 1.33 | [Recurrent facial palsy, primary Gougerot-Sjögren's syndrome and vitamin B12 deficiency]. ( Andrès, E; Blicklé, JF; Brogard, JM; Noel, E; Rousso, E, 2005) |
| "Prednisone was used at a starting dose from about 0." | 1.33 | Muscle involvement in sarcoidosis: a retrospective and followup studies. ( Bardin, T; Berenbaum, F; Fayad, F; Lioté, F; Orcel, P, 2006) |
| "Hydroxychloroquine was prescribed with clinical improvement." | 1.31 | [Primary Gougerot-Sjögren syndrome in a 13-year-old girl]. ( Boutté, P; Michiels, J; Monteilh, C; Sirvent, N; Thouret, MC; Triolo, V, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (5.80) | 18.7374 |
| 1990's | 9 (13.04) | 18.2507 |
| 2000's | 12 (17.39) | 29.6817 |
| 2010's | 31 (44.93) | 24.3611 |
| 2020's | 13 (18.84) | 2.80 |
| Authors | Studies |
|---|---|
| Majzoobi, MM | 1 |
| Hashmi, SH | 1 |
| Emami, K | 1 |
| Soltanian, AR | 1 |
| Yavropoulou, MP | 1 |
| Filippa, MG | 1 |
| Panopoulos, S | 1 |
| Spanos, E | 1 |
| Spanos, G | 1 |
| Tektonidou, MG | 1 |
| Sfikakis, PP | 1 |
| Basheer, A | 1 |
| Khan, EA | 1 |
| Hashmi, T | 1 |
| Khan, RA | 1 |
| Ahmad, A | 1 |
| Zen, M | 1 |
| Saccon, F | 1 |
| Gatto, M | 1 |
| Montesso, G | 1 |
| Larosa, M | 1 |
| Benvenuti, F | 1 |
| Iaccarino, L | 1 |
| Doria, A | 2 |
| Zeh, HJ | 1 |
| Bahary, N | 1 |
| Boone, BA | 1 |
| Singhi, AD | 1 |
| Miller-Ocuin, JL | 1 |
| Normolle, DP | 1 |
| Zureikat, AH | 1 |
| Hogg, ME | 1 |
| Bartlett, DL | 1 |
| Lee, KK | 1 |
| Tsung, A | 1 |
| Marsh, JW | 1 |
| Murthy, P | 1 |
| Tang, D | 1 |
| Seiser, N | 1 |
| Amaravadi, RK | 2 |
| Espina, V | 1 |
| Liotta, L | 1 |
| Lotze, MT | 1 |
| Lazaros, G | 1 |
| Antonopoulos, AS | 1 |
| Antonatou, K | 1 |
| Skendros, P | 1 |
| Ritis, K | 1 |
| Hadziyannis, E | 1 |
| Lazarou, E | 1 |
| Leontsinis, I | 1 |
| Simantiris, S | 1 |
| Vlachopoulos, C | 1 |
| Tousoulis, D | 1 |
| Vassilopoulos, D | 1 |
| Cai, S | 1 |
| Sun, W | 1 |
| Li, M | 1 |
| Dong, L | 1 |
| Györfi, AH | 1 |
| Kopp, M | 1 |
| May, M | 1 |
| Vetter, M | 1 |
| Uder, M | 1 |
| Kremer, AE | 1 |
| Schett, G | 1 |
| Harrer, T | 1 |
| Distler, JHW | 1 |
| He, F | 1 |
| Luo, Q | 1 |
| Lei, M | 1 |
| Fan, L | 1 |
| Shao, X | 1 |
| Hu, K | 1 |
| Qin, S | 1 |
| Yu, N | 1 |
| Cao, J | 1 |
| Yang, L | 1 |
| Riva, E | 1 |
| Sainaghi, PP | 1 |
| Turriziani, O | 1 |
| Antonelli, G | 1 |
| Patti, G | 1 |
| Nasiri, S | 1 |
| Dadkhahfar, S | 1 |
| Abasifar, H | 1 |
| Mortazavi, N | 1 |
| Gheisari, M | 1 |
| Mamishi, S | 1 |
| Navaeian, A | 1 |
| Shabanian, R | 1 |
| Fanouriakis, A | 1 |
| Tziolos, N | 1 |
| Bertsias, G | 1 |
| Boumpas, DT | 1 |
| Mathian, A | 1 |
| Pha, M | 1 |
| Amoura, Z | 1 |
| Scott, EC | 2 |
| Maziarz, RT | 1 |
| Spurgeon, SE | 1 |
| Medvedova, E | 1 |
| Gajewski, J | 1 |
| Reasor-Heard, S | 1 |
| Park, B | 1 |
| Kratz, A | 1 |
| Thomas, GV | 1 |
| Loriaux, M | 1 |
| Cascio, M | 1 |
| Podolak, J | 1 |
| Gordon, M | 1 |
| Botelho, J | 1 |
| Stadtmauer, E | 1 |
| Amaravadi, R | 1 |
| Vogl, DT | 2 |
| Rutledge, GG | 1 |
| Marr, I | 1 |
| Huang, GKL | 1 |
| Auburn, S | 1 |
| Marfurt, J | 1 |
| Sanders, M | 1 |
| White, NJ | 1 |
| Berriman, M | 1 |
| Newbold, CI | 1 |
| Anstey, NM | 1 |
| Otto, TD | 1 |
| Price, RN | 1 |
| Gan, SP | 1 |
| Ong, SG | 1 |
| Honda, F | 1 |
| Tsuboi, H | 1 |
| Toko, H | 1 |
| Ohyama, A | 1 |
| Takahashi, H | 1 |
| Abe, S | 1 |
| Yokosawa, M | 1 |
| Asashima, H | 1 |
| Hagiwara, S | 1 |
| Hirota, T | 1 |
| Kondo, Y | 1 |
| Matsumoto, I | 1 |
| Sumida, T | 1 |
| Lin, YC | 1 |
| Huang, HH | 1 |
| Nong, BR | 1 |
| Liu, PY | 1 |
| Chen, YY | 1 |
| Huang, YF | 1 |
| Chiou, YH | 1 |
| Lee, HS | 1 |
| van Roeden, SE | 1 |
| Bleeker-Rovers, CP | 1 |
| Kampschreur, LM | 1 |
| de Regt, MJA | 1 |
| Vermeulen Windsant, A | 1 |
| Hoepelman, AIM | 1 |
| Wever, PC | 1 |
| Oosterheert, JJ | 1 |
| Sun, Y | 1 |
| Ma, L | 1 |
| Chen, H | 1 |
| Kong, X | 1 |
| Lv, P | 1 |
| Dai, X | 1 |
| Ji, Z | 1 |
| Yang, C | 1 |
| Dai, S | 1 |
| Wu, L | 1 |
| Zou, Y | 1 |
| Lin, J | 1 |
| Shi, H | 1 |
| Yu, Q | 1 |
| Jiang, L | 1 |
| Vera-Ramirez, L | 1 |
| Vodnala, SK | 1 |
| Nini, R | 1 |
| Hunter, KW | 1 |
| Green, JE | 1 |
| Ghasemnejad-Berenji, H | 1 |
| Ghaffari Novin, M | 1 |
| Hajshafiha, M | 1 |
| Nazarian, H | 1 |
| Hashemi, SM | 1 |
| Ilkhanizadeh, B | 1 |
| Ghasemnejad, T | 1 |
| Sadeghpour, S | 1 |
| Ghasemnejad-Berenji, M | 1 |
| Néel, A | 1 |
| Hello, M | 1 |
| Cottereau, A | 1 |
| Graveleau, J | 1 |
| De Faucal, P | 1 |
| Costedoat-Chalumeau, N | 2 |
| Rondeau-Lutz, M | 1 |
| Lavigne, C | 1 |
| Chiche, L | 1 |
| Hachulla, E | 3 |
| Seiberras, S | 1 |
| Cabane, J | 1 |
| Tournemaine, N | 1 |
| Hamidou, M | 1 |
| Gunn, TM | 1 |
| Raz, GM | 1 |
| Turek, JW | 1 |
| Farivar, RS | 1 |
| Yates, M | 1 |
| Loke, YK | 1 |
| Watts, RA | 1 |
| MacGregor, AJ | 1 |
| Khayat, R | 1 |
| Dupuy, A | 1 |
| Pansé, I | 1 |
| Bagot, M | 1 |
| Cordoliani, F | 1 |
| Park, IC | 1 |
| Baek, YH | 1 |
| Han, SY | 1 |
| Lee, SW | 2 |
| Chung, WT | 1 |
| Kang, SH | 1 |
| Cho, DS | 1 |
| Zhang, LN | 1 |
| Shi, TY | 1 |
| Yang, YJ | 1 |
| Zhang, FC | 1 |
| Stadtmauer, EA | 1 |
| Tan, KS | 1 |
| Heitjan, DF | 1 |
| Davis, LE | 1 |
| Pontiggia, L | 1 |
| Rangwala, R | 1 |
| Piao, S | 1 |
| Chang, YC | 1 |
| Paul, TM | 1 |
| Nichols, CW | 1 |
| Porter, DL | 1 |
| Kaplan, J | 1 |
| Mallon, G | 1 |
| Bradner, JE | 1 |
| Lochouarn, M | 1 |
| Lagier, JC | 2 |
| Raoult, D | 2 |
| Pulcini, C | 1 |
| Mekinian, A | 1 |
| Masseau, A | 1 |
| Botta, A | 1 |
| Chudzinski, A | 1 |
| Theulin, A | 1 |
| Emmanuelli, V | 1 |
| De Carolis, S | 1 |
| Revaux, A | 1 |
| Nicaise, P | 1 |
| Cornelis, F | 1 |
| Subtil, D | 1 |
| Montestruc, F | 1 |
| Bucourt, M | 1 |
| Chollet-Martin, S | 1 |
| Carbillon, L | 1 |
| Fain, O | 1 |
| Vincent, D | 1 |
| Ponard, D | 1 |
| Fiorella, S | 1 |
| Drouet, C | 1 |
| Emonet, S | 1 |
| Wuillemin, T | 1 |
| Harbarth, S | 1 |
| Wassilew, N | 1 |
| Cikirikcioglu, M | 1 |
| Schrenzel, J | 1 |
| van Delden, C | 1 |
| Julkunen, H | 2 |
| Prior-Español, Á | 1 |
| Martínez-Morillo, M | 1 |
| Riveros-Frutos, A | 1 |
| Olivé, A | 1 |
| Hashemie, H | 1 |
| Klossowski, N | 1 |
| Oommen, PT | 1 |
| Neubert, J | 1 |
| Homey, B | 1 |
| Hoff, NP | 1 |
| Reifenberger, J | 1 |
| Meller, S | 1 |
| Hartman, O | 1 |
| Kovanen, PT | 1 |
| Lehtonen, J | 1 |
| Eklund, KK | 1 |
| Sinisalo, J | 1 |
| ALVING, AS | 1 |
| Pisoni, CN | 1 |
| Brucato, A | 1 |
| Ruffatti, A | 1 |
| Espinosa, G | 1 |
| Cervera, R | 1 |
| Belmonte-Serrano, M | 1 |
| Sánchez-Román, J | 1 |
| García-Hernández, FG | 1 |
| Tincani, A | 1 |
| Bertero, MT | 1 |
| Hughes, GR | 1 |
| Khamashta, MA | 1 |
| Chen, YA | 1 |
| Hsu, CK | 1 |
| Lee, JY | 1 |
| Yang, CC | 1 |
| Maschi, C | 1 |
| Tieulié, N | 1 |
| Gastaud, P | 1 |
| Baillif, S | 1 |
| Hong, YJ | 1 |
| Yang, SY | 1 |
| Lee, K | 1 |
| Kim, TS | 1 |
| Kim, HB | 1 |
| Park, KU | 1 |
| Song, J | 1 |
| Kim, EC | 1 |
| Galeone, M | 1 |
| Arunachalam, M | 1 |
| Scarfì, F | 1 |
| Palleschi, GM | 1 |
| Massi, D | 1 |
| Difonzo, EM | 1 |
| Singhal, S | 1 |
| Zahid, M | 1 |
| Verstappen, SM | 1 |
| van Albada-Kuipers, GA | 1 |
| Bijlsma, JW | 1 |
| Blaauw, AA | 1 |
| Schenk, Y | 1 |
| Haanen, HC | 1 |
| Jacobs, JW | 1 |
| Lowry, TR | 1 |
| Rousso, E | 1 |
| Noel, E | 1 |
| Brogard, JM | 1 |
| Blicklé, JF | 1 |
| Andrès, E | 1 |
| Aries, PM | 1 |
| Reinhold-Keller, E | 1 |
| Fayad, F | 1 |
| Lioté, F | 1 |
| Berenbaum, F | 1 |
| Orcel, P | 1 |
| Bardin, T | 1 |
| Batioğlu, F | 1 |
| Taner, P | 1 |
| Aydintuğ, OT | 1 |
| Heper, AO | 1 |
| Ozmert, E | 1 |
| Callejas-Rubio, JL | 1 |
| Rios-Fernández, R | 1 |
| Tomás-Jiménez, C | 1 |
| Ortego-Centeno, N | 1 |
| Modi, S | 1 |
| Rosen, T | 1 |
| Runge, LA | 1 |
| Krajnc, I | 1 |
| Louis, E | 1 |
| Belaïche, J | 1 |
| Lewis, JE | 1 |
| Beutner, EH | 2 |
| Rostami, R | 1 |
| Chorzelski, TP | 2 |
| Sibilia, J | 1 |
| Cribier, B | 1 |
| Javier, RM | 1 |
| Pflumio, F | 1 |
| Kuntz, JL | 1 |
| Yi, KJ | 1 |
| Chung, MH | 1 |
| Kim, HS | 1 |
| Kim, CS | 1 |
| Pai, SH | 1 |
| Shteyngarts, AR | 1 |
| Warner, MR | 1 |
| Camisa, C | 2 |
| Al-Mayouf, SM | 1 |
| Ghonaium, A | 1 |
| Bahabri, S | 1 |
| Arnal, C | 1 |
| Piette, JC | 1 |
| Léone, J | 1 |
| Taillan, B | 1 |
| Roudot-Thoraval, F | 1 |
| Papo, T | 1 |
| Schaeffer, A | 1 |
| Bierling, P | 1 |
| Godeau, B | 1 |
| Thouret, MC | 1 |
| Sirvent, N | 1 |
| Triolo, V | 1 |
| Monteilh, C | 1 |
| Michiels, J | 1 |
| Boutté, P | 1 |
| Petersen, CS | 1 |
| Thomsen, K | 1 |
| Parodi, A | 1 |
| Schosser, R | 1 |
| Guin, J | 1 |
| Cardo, PP | 1 |
| Maciejowska, E | 1 |
| Valeski, JE | 1 |
| Kumar, V | 1 |
| Allen, CM | 1 |
| Hamzeh, S | 1 |
| Stephens, L | 1 |
| Spann, CR | 1 |
| Callen, JP | 1 |
| Klein, JB | 1 |
| Kulick, KB | 1 |
| Snyder, GG | 1 |
| McCarthy, RE | 1 |
| Toomey, JM | 1 |
| Rothfield, NF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Impaired Functional Reserve of Adrenal Cortex May Associate With difficult-to Treat RA: Can a Disturbed Cortisol Circadian Rhythm Serve as a Predictor of Difficult-to-treat RA?[NCT05671627] | 50 participants (Anticipated) | Observational | 2022-02-02 | Recruiting | |||
| Optimization of Glucocorticoid Taper Strategies for Maintenance Therapy of Systemic Lupus Erythematosus Associated Immune Thrombocytopenia (SLE-ITP)[NCT05506033] | 120 participants (Anticipated) | Interventional | 2022-08-15 | Enrolling by invitation | |||
| Safety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care: A Double-blind Randomized Control Trial[NCT04397328] | Phase 3 | 336 participants (Anticipated) | Interventional | 2020-05-19 | Not yet recruiting | ||
| A Phase I/II Trial of Hydroxychloroquine Added to Bortezomib for Relapsed/Refractory Myeloma[NCT00568880] | Phase 1 | 25 participants (Actual) | Interventional | 2010-09-08 | Completed | ||
| PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) A Double-blind Placebo Controlled Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19[NCT04353037] | Phase 2 | 39 participants (Actual) | Interventional | 2020-04-07 | Terminated (stopped due to As enrollment began external studies called into question the safety and efficacy of hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy significantly impacted our ability to enroll and retain participants.) | ||
| Hydroxychloroquine for the Prevention of Recurrent Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial[NCT02648464] | Phase 4 | 125 participants (Actual) | Interventional | 2016-02-01 | Completed | ||
| Cyclophosphamide and Hydroxychloroquine for the Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus[NCT02444728] | Phase 3 | 50 participants (Actual) | Interventional | 2015-07-31 | Terminated (stopped due to Because of insufficient enrollement) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 1-3 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 4 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 15-17 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 6 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Co-inhabitants of COVID-19 positive PCR patients in self-quarantine that test positive up to 31 days after patient begins treatment with HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
if the participant gets COVID and has severe symptoms and hospitalized, end point reached if before the end of the 2 month period (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 months (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Number of COVID-19+ PCR patients in self-quarantine who are hospitalized up to 31 days after beginning HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Assessment of any medical events that occur during the ~60 day active period that is felt to be related to receipt of HCQ (NCT04353037)
Timeframe: Until completion of study, 2 months (~60 days) after start of treatment.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| moderate adverse events | minor adverse events | |
| Sub Study 2 Group 1 (HCQ) | 2 | 1 |
| Sub Study 2 Group 2 (Placebo) | 0 | 0 |
10 reviews available for hydroxychloroquine and Recrudescence
| Article | Year |
|---|---|
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
Topics: Aged; Anti-Bacterial Agents; Antifungal Agents; Antirheumatic Agents; Antiviral Agents; Arthritis, R | 2020 |
Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
Topics: Adult; Anti-Bacterial Agents; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Clinical Labo | 2020 |
Update οn the diagnosis and management of systemic lupus erythematosus.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Autoantibodies; Azathioprine; Calc | 2021 |
Cardiac manifestations of Q fever infection: case series and a review of the literature.
Topics: Adult; Anti-Bacterial Agents; Antirheumatic Agents; Aortic Coarctation; Aortic Valve Insufficiency; | 2013 |
Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dap | 2014 |
[Palindromic rheumatism or incipient rheumatoid arthritis--chances of drug therapy].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Humans; Hydroxychloroquine; Medica | 2014 |
Linear lupus panniculitis of the scalp presenting as alopecia along Blaschko's lines: a distinct variant of lupus panniculitis in East Asians?
Topics: Adult; Alopecia; Asian People; Humans; Hydroxychloroquine; Male; Panniculitis, Lupus Erythematosus; | 2012 |
Chronic ulcerative stomatitis with stratified epithelium-specific antinuclear antibodies.
Topics: Aged; Antibodies, Antinuclear; Antirheumatic Agents; Binding Sites, Antibody; Biomarkers; Biopsy; Ce | 1996 |
Lupus erythematosus associated with erythema multiforme: does Rowell's syndrome exist?
Topics: Adult; Azathioprine; Cathartics; Dermatologic Agents; Diagnosis, Differential; Erythema Multiforme; | 1999 |
Cheilitis granulomatosa: report of six cases and review of the literature.
Topics: Adult; Female; Humans; Hydroxychloroquine; Male; Melkersson-Rosenthal Syndrome; Middle Aged; Recurre | 1990 |
6 trials available for hydroxychloroquine and Recrudescence
| Article | Year |
|---|---|
Combination of doxycycline, streptomycin and hydroxychloroquine for short-course treatment of brucellosis: a single-blind randomized clinical trial.
Topics: Anti-Bacterial Agents; Brucellosis; Doxycycline; Drug Therapy, Combination; Humans; Hydroxychloroqui | 2022 |
A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Autophagy; | 2020 |
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Boronic Acids; Bortezomib; D | 2014 |
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Boronic Acids; Bortezomib; D | 2014 |
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Boronic Acids; Bortezomib; D | 2014 |
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Boronic Acids; Bortezomib; D | 2014 |
Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial.
Topics: Antirheumatic Agents; Atherosclerosis; Double-Blind Method; Humans; Hydroxychloroquine; Myocardial I | 2017 |
A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Follow-Up Studies; Humans; Hydroxy | 2005 |
Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Danazol; Drug Administration Routes; Dru | 2002 |
53 other studies available for hydroxychloroquine and Recrudescence
| Article | Year |
|---|---|
Impaired adrenal cortex reserve in patients with rheumatic and musculoskeletal diseases who relapse upon tapering of low glucocorticoid dose.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Adrenal Insufficiency; Antirheumatic Agents; Arthritis, Rhe | 2022 |
Recurrent aseptic meningitis: A rare clinical presentation of Sjogren's syndrome.
Topics: Antibodies, Antinuclear; Antirheumatic Agents; Fatigue; Female; Glucocorticoids; Humans; Hydroxychlo | 2019 |
Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.
Topics: Adult; Antimalarials; Antirheumatic Agents; Azathioprine; Cyclosporine; Deprescriptions; Female; Hum | 2020 |
Hydroxychloroquine for colchicine-resistant glucocorticoid-dependent idiopathic recurrent pericarditis: A pilot observational prospective study.
Topics: Colchicine; Glucocorticoids; Humans; Hydroxychloroquine; Pericarditis; Prospective Studies; Recurren | 2020 |
Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis.
Topics: Chronic Disease; COVID-19; Glucocorticoids; Humans; Hydroxychloroquine; Recurrence; Sarcoidosis | 2021 |
SARS-CoV-2 infection: diagnostic testing results occasionally require special attention.
Topics: Antibodies, Viral; Betacoronavirus; Coronavirus Infections; COVID-19; Enzyme-Linked Immunosorbent As | 2020 |
Urticarial vasculitis in a COVID-19 recovered patient.
Topics: Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Histamine Antago | 2020 |
Acute aortic dissection in a patient with Williams syndrome infected by COVID-19.
Topics: Adolescent; Anti-Bacterial Agents; Antiviral Agents; Aortic Aneurysm; Aortic Dissection; Aortic Sten | 2021 |
[Therapeutic de-escalation in systemic lupus erythematosus in remission].
Topics: Dose-Response Relationship, Drug; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Mainten | 2020 |
Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Bone Marrow; Cel | 2017 |
Genomic Characterization of Recrudescent Plasmodium malariae after Treatment with Artemether/Lumefantrine.
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Dr | 2017 |
Antithrombotic effects of hydroxychloroquine in a pregnant patient with Antiphospholipid syndrome and recurrent venous thromboembolism.
Topics: Antiphospholipid Syndrome; Antithrombins; Female; Humans; Hydroxychloroquine; Pregnancy; Pregnancy C | 2017 |
Recurrent Kikuchi-Fujimoto Disease Successfully Treated by the Concomitant Use of Hydroxychloroquine and Corticosteroids.
Topics: Adult; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Histiocytic Necrotizing | 2017 |
Pediatric Kikuchi-Fujimoto disease: A clinicopathologic study and the therapeutic effects of hydroxychloroquine.
Topics: Adolescent; Adrenal Cortex Hormones; Biopsy; Child; Diagnosis, Differential; Female; Histiocytic Nec | 2019 |
The effect of measuring serum doxycycline concentrations on clinical outcomes during treatment of chronic Q fever.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Doxycycline; Drug Monitoring; Female; Humans; Hydrox | 2018 |
Analysis of predictive factors for treatment resistance and disease relapse in Takayasu's arteritis.
Topics: Adult; Age Factors; Benzimidazoles; Blood Sedimentation; C-Reactive Protein; China; Cyclophosphamide | 2018 |
Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence.
Topics: Adenine; Animals; Autophagy; Autophagy-Related Protein 7; Beclin-1; Breast Neoplasms; Caspases; Cell | 2018 |
Immunomodulatory effects of hydroxychloroquine on Th1/Th2 balance in women with repeated implantation failure.
Topics: Adult; Embryo Implantation; Female; Fertilization in Vitro; Humans; Hydroxychloroquine; Immunomodula | 2018 |
Long-term outcome in idiopathic granulomatous mastitis: a western multicentre study.
Topics: Adult; Colchicine; Drug Utilization; Female; Glucocorticoids; Granulomatous Mastitis; Humans; Hydrox | 2013 |
[Sclerodermatous changes in porphyria cutanea tarda: six cases].
Topics: Adrenal Cortex Hormones; Aged; Alcoholism; Alopecia; Diagnosis, Differential; Female; Humans; Hydrox | 2013 |
Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy.
Topics: Adolescent; Anticoagulants; Antiphospholipid Syndrome; Chemical and Drug Induced Liver Injury; Clopi | 2013 |
An SLE patient with prolactinoma and recurrent granulomatous mastitis successfully treated with hydroxychloroquine and bromocriptine.
Topics: Bromocriptine; Female; Granulomatous Mastitis; Hormone Antagonists; Humans; Hydroxychloroquine; Lupu | 2014 |
A case of Whipple's disease evolving over 30 years.
Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Aortic Valve Insufficiency; Biopsy; Disease Progressio | 2014 |
Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study.
Topics: Abortion, Habitual; Adult; Aspirin; Autoantibodies; Autoimmune Diseases; Cell Movement; Chorionic Vi | 2015 |
Benefits of hydroxychloroquine in the treatment of a patient with angioedema due to acquired C1 inhibitor deficiency.
Topics: Aged; Angioedema; Angioedemas, Hereditary; Antibodies, Blocking; Autoantibodies; Autoimmunity; Compl | 2015 |
Relapse of Tropheryma whipplei endocarditis treated by trimethoprim/sulfamethoxazole, cured by hydroxychloroquine plus doxycycline.
Topics: Anti-Bacterial Agents; Aortic Valve; Ceftriaxone; Doxycycline; Drug Therapy, Combination; Endocardit | 2015 |
[Recurrent diffuse alveolar hemorrhage in systemic lupus erytematosus treated with rituximab and immunoglobulins].
Topics: Cyclophosphamide; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxychloroquine; Immunoglobulins | 2015 |
[Juvenile systemic lupus erythematosus with unusual manifestation of lupus-associated panniculitis].
Topics: Adolescent; Anti-Inflammatory Agents; Diagnosis, Differential; Drug Therapy, Combination; Humans; Hy | 2015 |
Successful Treatment of Intermittent Hydrarthrosis With Hydroxychloroquine.
Topics: Antirheumatic Agents; Diagnosis, Differential; Female; Humans; Hydrarthrosis; Hydroxychloroquine; Kn | 2015 |
Study of pentaquine and isopentaquine, therapeutic agents effective in reducing relapse rate in vivax malaria.
Topics: Aminoquinolines; Hydroxychloroquine; Hydroxyquinolines; Malaria; Malaria, Vivax; Recurrence | 1948 |
Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study.
Topics: Autoantigens; Dexamethasone; Drug Therapy, Combination; Female; Heart Block; Heart Defects, Congenit | 2010 |
Use of hydroxychloroquine in corticodependent and recurrent scleritis.
Topics: Adult; Antirheumatic Agents; Drug Therapy, Combination; Glucocorticoids; Humans; Hydroxychloroquine; | 2013 |
A case of imported Plasmodium malariae malaria.
Topics: Antimalarials; Drug Resistance; Female; Humans; Hydroxychloroquine; Malaria; Mefloquine; Plasmodium | 2012 |
Unilateral eyelid involvement in discoid lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Blepharitis; Chalazion; Female; Humans; Hydroxychloroquine; Lupus Eryth | 2014 |
Palindromic rheumatism.
Topics: Adult; Drug Administration Schedule; Finger Joint; Humans; Hydroxychloroquine; India; Male; Pain Mea | 2002 |
Sarcoidosis of nasal ala and lower lip.
Topics: Adult; Biopsy; Dermatologic Agents; Humans; Hydroxychloroquine; Male; Mouth Diseases; Nose Diseases; | 2004 |
[Recurrent facial palsy, primary Gougerot-Sjögren's syndrome and vitamin B12 deficiency].
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Electromyography; Facial Paralysis; Female; H | 2005 |
[Symmetric polyarthritis in a patient with Churg-Strauss syndrome].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis; Azathioprine; Churg-Strauss Syndrome; Cyclo | 2005 |
Muscle involvement in sarcoidosis: a retrospective and followup studies.
Topics: Adult; Cardiomyopathies; Chronic Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studie | 2006 |
Recurrent optic disc and retinal vasculitis in a patient with drug-induced urticarial vasculitis.
Topics: Anti-Infective Agents; Dermatologic Agents; Drug Industry; Drug Therapy, Combination; Female; Glucoc | 2006 |
Corticosteroids in preventing severe lupus flares: do all patients have the same risk? Comment on the article by Tseng et al.
Topics: Adrenal Cortex Hormones; Antibodies, Anti-Idiotypic; Antirheumatic Agents; DNA; Dose-Response Relati | 2007 |
Micropapular cutaneous sarcoidosis: case series successfully managed with hydroxychloroquine sulfate.
Topics: Adult; Antirheumatic Agents; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Male; Recu | 2008 |
Risk/benefit analysis of hydroxychloroquine sulfate treatment in rheumatoid arthritis.
Topics: Actuarial Analysis; Arthritis, Rheumatoid; Gastrointestinal Diseases; Gold; Humans; Hydroxychloroqui | 1983 |
[Palindromic rheumatism--progression to erosive rheumatoid arthritis--presentation of 3 years treatment of a patient].
Topics: Adult; Arthritis, Rheumatoid; Arthrography; Diagnosis, Differential; Follow-Up Studies; Humans; Hydr | 1995 |
Hydroxychloroquine (Plaquenil) for recurrence prevention of Crohn's disease after curative surgery.
Topics: Crohn Disease; Humans; Hydroxychloroquine; Postoperative Care; Recurrence | 1995 |
Recurrent psoriatic onychoperiostitis induced by hydroxychloroquine.
Topics: Female; Humans; Hydroxychloroquine; Middle Aged; Nail Diseases; Periostitis; Psoriasis; Recurrence; | 1995 |
A relapsed case of imported tertian malaria after a standard course of hydroxychloroquine and primaquine therapy.
Topics: Adult; Animals; Antimalarials; Humans; Hydroxychloroquine; Malaria, Vivax; Male; Primaquine; Recurre | 1998 |
Hypergammaglobulinaemic purpura associated with IgG subclass imbalance and recurrent infection.
Topics: Child, Preschool; Disease Progression; Humans; Hydroxychloroquine; Immunoglobulin G; Infections; Mal | 2000 |
[Primary Gougerot-Sjögren syndrome in a 13-year-old girl].
Topics: Adolescent; Antirheumatic Agents; Biopsy; Female; Humans; Hydroxychloroquine; Parotitis; Recurrence; | 2002 |
High-dose hydroxychloroquine treatment of porphyria cutanea tarda.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Female; Follow-Up Studies; Humans; Hyd | 1992 |
Ten cases of chronic ulcerative stomatitis with stratified epithelium-specific antinuclear antibody.
Topics: Adult; Aged; Antibodies, Antinuclear; Chronic Disease; Female; Fluorescent Antibody Technique; Gingi | 1991 |
Clinical, serologic and immunogenetic studies in patients with chronic cutaneous (discoid) lupus erythematosus who have verrucous and/or hypertrophic skin lesions.
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Antinuclear; Chronic Disease; DNA, Single-Stranded; Fema | 1988 |
Nasal septal perforation in systemic lupus erythematosus.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Epistaxis; Female; Fluorescent Ant | 1974 |